MEG3 and osteosarcoma: Moreover, the decreased expression of MEG3 was associated with advanced clinical stage, which was similar to Zhuo et al finding in breast cancer19 and Tian et al finding in osteosarcoma.26 Taken together, our findings suggest that MEG3 may serve as a novel biomarker for the progress of laryngeal cancer.